Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1

Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1

Hormonal therapies for prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD). Clinical development for inhibitors that bind to the N-terminal domain (NTD) of AR has yielded ralaniten and its analogues. Ralaniten acetate is well tolerated in patients at 3600 mgs/day. Clinical...

Full description

Bibliographic Details
Main Authors: Jon K. Obst, Nasrin R. Mawji, Simon J. L. Teskey, Jun Wang, Marianne D. Sadar
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
prostate cancer
metallothionein
androgen receptor
ralaniten
off-target
sintokamide
Online Access:https://www.mdpi.com/2072-6694/14/2/386

Internet

https://www.mdpi.com/2072-6694/14/2/386

Similar Items